Aurinia Pharmaceuticals (AUPH)

• Market cap: $1.06B
• 1 day: -1.16%
• 5 days: 1.32%
• 1 month: -9.24%
• 3 months: -0.91%
• 6 months: 6.83%
• Year to date: -12.66%
• 1 year: 51.68%
• 5 years: -51.91%
• 10 years: 101.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

111% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 18

31% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 48

23% more capital invested

Capital invested by funds: $422M [Q3] → $518M (+$96.2M) [Q4]

9% more funds holding

Funds holding: 179 [Q3] → 196 (+17) [Q4]

0.02% more ownership

Funds ownership: 40.29% [Q3] → 40.3% (+0.02%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

21% less call options, than puts

Call options by funds: $13.3M | Put options by funds: $16.8M